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ABSTRACT
Background and the purpose of the study: Lercanidipine hydrochloride (LRDP) is used in the 
treatment of hypertension because of its selectivity and specificity on the smooth vascular cells. 
The pharmacokinetic parameters make LRDP a suitable candidate for transdermal delivery. The 
purpose of the study was to select a suitable formulation for the development of transdermal 
drug-delivery system (TDDS) of LRDP and to determine the effect of penetration enhancer, 
limonene on drug permeation
Methods: The matrix type TDDS of LRDP were prepared by solvent evaporation technique. 
Formulations  A1, A2, A3, A4, A5 and A6 were composed of Eudragit RL100 (ERL) and 
hydroxypropyl  methyl  cellulose  (HPMC)  in  1.5:8.5,  3:7,  4:6,  6:4,  7:3  and  8.5:1.5  ratios 
respectively. All the six formulations carried 10 mg of LRDP/patch area, 8 % v/w of d-limonene 
as  a  penetration  enhancer,  20  %  v/w  of  propylene  glycol  as  plasticizer  in  methanol  and 
dichloromethane as solvent system. The prepared TDDS were evaluated for physicochemical 
characteristics, in-vitro release, ex-vivo permeation and skin irritation. The ex-vivo permeation 
studies were carried out across excised rat skin using Franz diffusion cell.    
Results: All the formulations exhibited satisfactory physicochemical characteristics. Cumulative 
percentage of the drug released in 24 hrs from the six formulations were 82.0 %, 74.9 %, 63.2 %, 
63.5 %, 59.8 % and 53.5 % respectively. Corresponding values for the cumulative amounts of 
the drug permeated across the rat skin for the above matrix films were 2644.5, 2347.2, 2249.5, 
1933.4, 2021.5 and 1663.4 µg/cm2 respectively. By fitting the data into zero order, first order and 
Higuchi model, it was concluded that drug release from matrix films followed Higuchi model 
and the mechanism of the drug release was diffusion mediated. The patches were seemingly free 
of potentially hazardous skin irritation.
Conclusions: The patches composed of ERL, HPMC (1.5:8.5) with 8 % v/w limonene as 
penetration enhancer may be selected for the development of TDDS of LRDP for potential 
therapeutic use by using a suitable adhesive layer and backing membrane. 
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INTRODUCTION
It  has  been  shown  that  transdermal  route  of 
administration is not subjected to the hepatic first 
pass  effect  which  result  in  the  required  systemic 
bioavailability of the drug (1). However, the success 
of  a  transdermal  drug  delivery  system  (TDDS) 
depends on the ability of the drug to penetrate the 
skin in sufficient quantities to maintain therapeutic 
levels. Several methods have been reported in the 
literature  to  enhance  the  drug  penetration  across 
biological  membranes  (2).    For  many  therapeutic 
agents, the desired effect may not be possible without 
the use of penetration enhancers. An ideal enhancer 
should  be  pharmacologically  inactive,  nonirritant, 
and should not damage the skin irreversibly. Many of 
the chemical enhancers such as dimethyl sulfoxide, 
surfactants,  alcohols,  and  urea  and  its  derivatives 
have been screened as penetration enhancers. The 
adverse effects of some of these enhancers restrict 
their use widely. Currently, there has been an upsurge 
in the use of naturally occurring chemicals such as 
terpenes which are isolated from natural essential oils 
and are safe and non-irritating penetration enhancers 
(3). d-limonene, a cyclic terpene is free from toxic 
effects and has been used as a penetration enhancer in 
the transdermal delivery of several drugs (4,5). The 
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cm2 was used for ex vivo permeation studies. The 
rat  skin  was  mounted  between  the  compartments 
of diffusion cell with stratum corneum facing the 
donor compartment. LRDP solution (5 mg in 3 ml of 
phosphate buffered saline (PBS) of pH 7.4 containing 
PEG  400)  was  placed  in  the  donor  compartment 
containing  different  concentrations  of  d-limonene 
(0, 4, 8, 12 % v/v). The 0 % d-limonene served as 
control and PEG 400 was used to solubilize LRDP. 
The receiver compartment contained 13 ml of 40 
% v/v PEG 400 in PBS of pH 7.4 and the contents 
were  stirred  using  magnetic  stirrer.  The  whole 
assembly was kept at 37 ± 0.5 oC. Samples of 3 ml 
were collected at preset time points up to 24 hrs 
and replenished with 40 % v/v PEG 400 in PBS 
pH 7.4. The samples were filtered through 0.45 µ 
syringe filter (Sartorius AG, Goettingen, Germany) 
and  drug  content  in  the  samples  was  measured 
using  UV/visible  spectrophotometer  (Shimadzu 
Pharmspec1700, Shimadzu Inst. Japan) at 354 nm. 
The cumulative amount of the permeated drug was 
calculated.  
Analysis of permeation data and Statistics
The  drug  concentration  in  the  permeates  was 
corrected  for  sampling  effects  according  to  the 
equation described by Hayton and Chen (10).
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where,  A  is  the  effective  diffusion  area;  Cs,  the 
concentration in the saturated solution and (dQ/dt) ss 
is the steady state slope.
The penetration enhancing effect of d-limonene was 
calculated in terms of enhancement ratio (ER) by 
using the following equation (12).
The cumulative amount permeated and flux values 
obtained  were  tested  for  significant  differences 
use of Eudragit RL100 (ERL) and hydroxypropyl 
methyl cellulose (HPMC) in preparation of matrix 
patches has been reported (6).   
Lercanidipine hydrochloride (LRDP) is used in the 
treatment of hypertension because of its selectivity 
and specificity on the smooth vascular cells. The 
drug is administered orally at a dose of 10-20 mg 
daily  as  its  hydrochloride  salt  and  reduces  the 
diastolic blood pressure significantly (7). After oral 
administration, LRDP is completely and erratically 
absorbed  from  the  gastrointestinal  tract  (8).  The 
absolute bioavailability is reduced to approximately 
10 % because of its extensive first pass metabolism 
to inactive metabolites (7). Mean half-lives of the 
drug has been reported 2.8 and 4.4 hrs in human after 
single dose of 10 and 20 mg of LRDP, respectively 
(8). These pharmacokinetic parameters make LRDP 
a suitable candidate for transdermal delivery. 
In the present investigation, an attempt was made to 
deliver LRDP transdermally via patches to overcome 
drawback of poor oral bioavailability and erratic oral 
absorption. Survey of literature and patent databases 
did  not  reveal  any  transdermal  dosage  form  of 
LRDP for the purpose of improving bioavailability. 
Hence, the objective of present investigation was to 
formulate  transdermal  polymeric  films  with  ERL 
and HPMC containing LRDP using d-limonene as 
permeation enhancer and to evaluate them by ex vivo 
permeation studies.
MATERIAL  AND  METHODS
Materials
Lercanidipine  hydrochloride  and  Eudragit  RL 
100 were gifts samples from Sun Pharmaceuticals 
(Baroda,  India),  and  Aurobindo  Pharmaceuticals 
(Hyderabad,  India)  respectively.  d-Limonene  was 
purchased  from  Himedia,  Mumbai,  India.  Liquid 
mercury,  hydroxypropyl  methyl  cellulose  15  cps 
(HPMC), propylene glycol (PG), polyethyleneglycol 
400  (PEG  400)  were  purchased  from  SD  Fine 
Chemicals, Mumbai, India.
Methods
Preparation of rat abdominal skin
Albino rats weighing 150-200 gm were selected for 
permeation  studies.  The  animals  were  sacrificed 
using anesthetic ether. The hair of the test animals 
was carefully trimmed short with a pair of scissors 
and the full thickness skin was removed from the 
abdominal  region.  The  epidermis  was  prepared 
surgically by heat separation technique (9), which 
involved  soaking  of  the  entire  abdominal  skin  in 
water at 60 °C for 45 sec, followed by careful removal 
of the epidermis. The epidermis was washed with 
water and used for ex vivo permeability studies. 
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Kp  with  penetration  enhancer
Kp without penetration enhancer
ER=11 Transdermal patches of lercanidipine hydrochloride
using a one-way analysis of variance (ANOVA) or 
unpaired t test.
Preparation of transdermal films
The  matrix  type  transdermal  patches  containing 
LRDP were prepared using different ratios of ERL 
and HPMC (Table 1). The polymers were weighed 
in  requisite  ratios  by  keeping  the  total  polymer 
weight at 1.0 gm and allowed to swell for 2 hrs in 
solvent  mixture  (3:2  ratio  of  dichloromethane, 
methanol).  The  drug  solution  was  added  to  the 
polymeric solution while stirring. Propylene glycol 
was incorporated as plasticizer and d-limonene as 
penetration enhancer. The solution was poured into 
a glass ring of about 26 cm2, placed on the surface of 
liquid mercury and kept in a petriplate. The solvent 
was allowed to evaporate for 24 hrs. Aluminum foil 
was used as backing film. The polymer was found 
to be self adhesive due to the presence of Eudragit 
polymer along with plasticizer. The patches were cut 
to give required area and used for evaluation.
Evaluation of physicochemical properties
Thickness and weight variation 
The thickness of patches was assessed at 6 different 
points using digital micrometer (Mitutoyo, Japan) 
and for each formulation, three randomly selected 
patches were used. For weight variation test, 3 films 
(each  2.64  cm2)  from  each  batch  were  weighed 
individually and the average weight was calculated.
Folding endurance 
The folding endurance was measured manually as 
the reported method (13).  Briefly, a strip of the film 
(4 x 3 cm) was cut evenly and repeatedly folded at 
the same place till it broke. 
Flatness 
Longitudinal strips were cut from the prepared patch, 
the length of each strip was measured and then the 
variation in the length due to the non-uniformity in 
flatness was measured. Flatness was calculated by 
measuring constriction of strips, and 0 % constriction 
was considered to be 100 % flatness (14). 
Determination of drug content 
Patch (2.64 cm2) from each formulation was taken, 
cut into small pieces and was allowed to dissolve in 
a 100 ml solution containing 15 ml of methanol and 
85 ml of 40% v/v PEG 400 in PBS pH 7.4. The 
solution was filtered, diluted suitably and the 
absorbance of the solution was measured using UV/
visible spectrophotometer at a wavelength of 354 nm 
against reference solution prepared with placebo films. 
Percentage of moisture content
The films were weighed individually and kept in 
a  desiccator  containing  activated  silica  at  room 
temperature for 24 hrs. The individual films were 
weighed  repeatedly  until  a  constant  weight  was 
achieved. The percentage of moisture content was 
calculated as the difference between initial and final 
weight with respect to the final weight (15). 
Percentage of moisture uptake
The films were weighed accurately and placed in a 
desiccator containing 200 ml of saturated solution of 
potassium chloride (84 % relative humidity) at room 
temperature.  After 3 days, the films were taken out 
and  weighed.  The  percentage  of  moisture  uptake 
was calculated as the difference between final and 
initial weight with respect to initial weight (13). 
In vitro release studies
The  in  vitro  release  study  was  carried  out  using 
Franz diffusion cell. The drug containing film with 
a support of backing membrane was sandwiched in 
a dialysis membrane with molecular weight cut off 
Code Drug (mg) Polymers Weight
(mg)
Thickness 
(µ)
 Folding
Endurance
Drug content 
(mg)
LRDP ERL : HPMC 
A1 100 1.5:8.5 131.5 ± 5.27 326 ± 6.53 30.3 ± 3.51 9.9 ± 0.59
A2 100 3:7 135.2 ± 2.82 301 ± 7.10 31.3 ± 1.52 10.3 ± 0.35
A3 100 4:6 124.7 ± 4.56 301 ± 3.34 26.7 ± 3.51 10.5 ± 0.39
A4 100 6:4 117.5 ± 6.53 275 ± 6.36 48.3 ± 4.50 10.1 ± 0.12
A5 100 7:3 119.0 ± 4.08 264 ± 2.26 46.0 ± 4.58 10.1 ± 0.28
A6 100 8.5:1.5 125.3 ± 2.98 250 ± 4.12 52.3 ± 2.51 10.5 ± 1.06
*Table 1. Composition and Physicochemical Properties of Lercanidipine  hydrochloride Transdermal  Patches
Note: Each patch (2.64 cm2) contained 10 mg of lercanidipine hydrochloride.
20 % v/w of propylene glycol to the total polymer weight, incorporated as plasticizer.
8 % v/w of d-limonene to the total polymer weight was used as penetration enhancer. 
*All values are expressed as mean ± SD (n=3). ERL indicates Eudragit RL 100; HPMC, Hydroxypropyl Methyl Cellulose.12 Mamatha et al / DARU 2010 18 (1) 9 -16
between 12000 to 14000 (Himedia, Mumbai, India) 
and was further placed between compartments of 
diffusion  cell.  The  dialysis  membrane  had  been 
soaked for 24 hrs in 40% v/v PEG 400 in PBS of 
pH 7.4. The donor compartment was open at the top 
and exposed to atmosphere. The donor and receptor 
compartments  held  together  using  a  clamp  and 
receptor compartment was provided with sampling 
port. The receptor compartments contained 13 ml of 
40% v/v PEG 400 in PBS of pH 7.4 and the contents 
were  stirred  at  a  speed  of  400  rpm.    The  whole 
assembly was kept on a magnetic stirrer and study 
was conducted at a temperature of 37 ± 0.5oC.  The 
samples of 3 ml were collected at preset time points 
up to 24 hrs and replenished with fresh medium.   
The  samples  were  filtered  using  syringe  filter 
(Sartorius 0.45µ) and drug content in the samples 
was estimated using UV/ visible spectrophotometer 
at 354 nm. Cumulative percentage of the released 
drug was calculated and plotted against time.
Ex-vivo permeation studies
Franz diffusion cell with a surface area of 2.64 cm2 
was used for ex-vivo permeation studies. Excised rat 
skin was mounted between the compartments of the 
diffusion cell with stratum corneum facing the donor 
compartment. The stratum corneum side of the skin 
was  kept  in  intimate  contact  with  the  transdermal 
patch under the test. The receiver compartment 
contained 13 ml of 40% v/v PEG 400 in PBS of pH 
7.4, stirred with a magnetic stirrer at a speed of 400 
rpm. The whole assembly was kept on a magnetic 
stirrer and study was conducted at 37 ± 0.5o C. The 
amount of the permeated drug was determined by 
removing 3 ml at preset time points up to 24 hrs and 
replenishing with an equal volume of fresh medium. 
The samples were filtered using syringe filter (Sartorius 
0.45µ) and the absorbance was measured at 354 nm 
spectrophotometrically.  The  cumulative  amount  of 
drug permeated was calculated and plotted against 
time.
Primary skin irritancy studies
The  study  was  conducted  on  the  basis  of  the 
approval of institutional animal ethical committee. 
Albino rabbits of either sex, each weighing 1.5 to 
2.0 kg were used in this study (n = 3 in each group). 
They  were  housed  in  cages  in  the  animal  house 
under controlled temperature and light conditions. 
They were fed a standard laboratory diet and had 
access to water ad libitum. The dorsal surface of the 
rabbits was cleared and the hair was removed by 
shaving. The skin was cleared with rectified spirit. 
The control patch (without any drug, group I) and 
an experimental patch (A1, group II) were applied 
to the shaved skin of rabbits and secured using USP 
adhesive tape (Johnson & Johnson limited, Mumbai). 
A 0.8 % (v/v) aqueous solution of formaldehyde was 
applied as a standard irritant (group III). Its effect 
was  compared  with  the  test.  The  animals  were 
observed for any sign of erythema and oedema for 
a period of 7 days and scored as reported by Draize 
et al. (16).
RESULTS  AND  DISCUSSION
Effect of d-limonene on permeation of LRDP
The  effect  of  concentration  of  d-limonene  on 
cumulative  permeation  through  rat  skin  is  shown 
in figure 1. Solution containing 8 and 12 % v/v of 
d-limonene  showed  similar  flux  values  (64.4  ± 
1.88 and 58.0 ± 1.38 µg/cm2/hr) and permeability 
coefficients (3.4 ± 0.09 and 3.1 ± 0.07 cm hr-1×10-2). 
The flux values obtained with 8 and 12 % v/v of 
d-limonene were significantly different (p< 0.05) to 
lowest values obtained with 4 % d-limonene (34.4   
± 1.47 µg/cm2/hr) and control (9.7 ± 1.08 µg/cm2/
hr).  The  permeability  coefficient  obtained  with  8 
and 12 % d-limonene were 6.2 and 5.5 times higher 
than that observed with control. The permeation of 
LRDP was not affected by increasing d-limonene 
concentration  from  8  to  12  %  v/v;  hence  in  the 
preparation of patches, d-limonene at concentration 
of 8 % v/v was incorporated.
The  effectiveness  of  hydrocarbon  limonene  has 
also  been  demonstrated  for  other  lipophilic  drugs 
such as ketoprofen and valsartan (17,18). The great 
enhancement  by  limonene  suggests  that  there  were 
possibly multiple mechanisms that could have resulted 
in a more permeable pathway for LRDP. They include 
an increased solubility of LRDP within skin, partial 
Figure 1. Effect of concentration of d-limonene on cumulative permeation, mean ± SD (n=3).
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Figure 1. Effect of concentration of d-limonene on cumulative 
permeation, mean ± SD (n=3).13 Transdermal patches of lercanidipine hydrochloride
extraction of stratum corneum (SC) lipids (19), phase 
separation within the SC lipid lamellae (20).
Physicochemical characterization of patches
The results of the physicochemical characterization 
of the patches are shown in table 1. The weights and 
thicknesses were found in the range of 117.5-135.2 
mg and 250-326 µ respectively. As the proportion of 
HPMC decreased, the thickness was also decreased. 
Good uniformity of drug content among the batches 
was observed for all formulations and ranged from 
9.9 to 10.5 mg.  The results indicate that the process 
which was employed to prepare patches in this study 
was capable to produce patches with uniform drug 
content and minimal patch variability. The flatness 
study  showed  that  all  formulations  had  the  same 
strip length before and after their cuts, indicating 
100 % flatness. As a result there was no constriction 
and all patches had a smooth, flat surface; and that 
smooth surface could be maintained when the patch 
was  applied  to  the  skin.  Folding  endurance  test 
results indicated that the patches did not break and 
maintained their integrity with general skin folding 
when  applied.  The  thinner  the  film  was,  more 
flexible it was.
The results of % moisture uptake and % moisture 
content studies are shown in figure 2. The results 
revealed  that  the  increase  in  the  concentration  of 
hydrophilic polymer was directly proportional to the 
increase in moisture content and moisture uptake of 
the patches. The % moisture content in the patches 
ranged from 3.2 to 6.2. The % moisture uptake in 
the formulations were in the range of 5.3 to 13.5. 
The integrity of formulations was not changed on 
moisture uptake. The low moisture content in the 
formulations resulted in stability of patches and not 
giving a completely dried and brittle film (21).
In-vitro release studies
The  results  of  in  vitro  drug  release  studies  from 
transdermal  patches  are  depicted  in  figure  3. 
Formulation A1 exhibited greatest (82) percentage 
of drug release, which was significantly (P<0.05) 
different  from  the  lowest  value  obtained  by 
Formulation
Code
Q24a
(%)
Q24b
(µg/cm2)
Jssc
(µg/cm2/hr)
Kpd
(cm hr-1×10-2)
A1 82.0 ±  8.93 2644.5 ± 91.73 106.5 ± 3.61 2.76 ± 0.093
A2 74.9 ± 10.42 2347.2 ± 83.74 94.2 ± 3.18 2.44 ± 0.082
A3 63.2 ± 9.46 2249.5 ± 60.25 92.5 ± 2.30 2.40 ± 0.059
A4 63.5 ± 11.43 1933.4 ± 79.42 82.1 ± 3.17 2.05 ± 0.082
A5 59.8 ± 5.34 2021.5 ± 68.40 87.2 ± 2.75 2.19 ± 0.071
A6 53.5 ± 8.46 1663.4 ± 58.37 72.1 ± 2.25 1.81 ± 0.058
 Table 2. In vitro Drug Release, Ex vivo Skin Permeation, Transdermal Flux and Permeability Coefficient of Lercanidipine  hydrochloride
Transdermal Patches
Q 24
a  Cumulative % of the drug that released, results are the mean ± SD of triplicate observations.
Q24
b Cumulative amount (µg) of the drug that permeated per cm2, results are mean ± SD of triplicate observations. 
Jssc Transdermal flux, values represent mean ± SD (n=3).
Kpd Permeability Coefficient, values represent mean ± SD (n=3).
Figure 2. Moisture uptake and moisture content of lercanidipine patches, mean ± S.D (n=3).
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Figure 2. Moisture uptake and moisture content of lercanidipine 
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Rabbit No Group I
(without any drug)
 Group II
(A1)
Group III
(Formalin)
Erythemaa Edemab Erythema Edema Erythema Edema
1 0 1 0 0 3 2
2 1 0 0 1 3 1
3 0 1 1 1 3 2
Average ±S.D 0.34±0.58* 0.67±0.58* 0.34± 0.58* 0.67±0.58* 3 ± 0 1.67±0.58
Table 3. Skin Irritation Scores Following Transdermal Patch Administration
*p < 0.05, significant compared with formalin.
a: Erythema scale: 0, none; 1, slight; 2, well defined; 3, moderate; and 4, scar formation.
b: Edema scale: 0, none; 1, slight; 2, well defined; 3, moderate; and 4, severe.
formulation A6 (53.5 %). In the present study, it was 
observed  that  as  the  concentration  of  hydrophilic 
polymer (HPMC) increased in the formulations, the 
drug release rate increased substantially. Addition of 
hydrophilic component to an insoluble film former 
tends to enhance the release rates.
Data  of  the  in  vitro  release  was  fit  into  different 
equations and kinetic models to explain the release 
kinetics of LRDP from transdermal patch. The kinetic 
models (22) used were zero-order equation, first-order 
equation,  Higuchi  and  Korsemeyer-Peppas  models. 
The cumulative amount of the drug released from the 
patches, when plotted against square-root of time, 
the release profiles of drug seemed to follow Higuchi 
model as it was evidenced by correlation coefficients 
(r2 = 0.98 to 0.99) better than zero order (r2 = 0.95 to 
0.98) and first order (r2 = 0.52 to 0.57). The data was 
further treated as per the following equation
 
Mt/M∞ = K. tn  
where, Mt/M∞ is the fractional release of the drug, 
Mt is the amount released at time t, M∞ is the total 
amount of drug contained in the transdermal patch, 
t is the release time, K is a kinetic constant, and n 
is the diffusional release exponent indicative of the 
Figure 3. In vitro release profile of LRDP from transdermal patches, mean ± SD (n=3). 
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Figure 4. Ex vivo permeation profile of LRDP from transdermal patches through rat 
abdominal skin, mean ± S.D (n=3)
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Figure  3.  In  vitro  release  profile  of  LRDP  from  transdermal 
patches, mean ± SD (n=3).
Figure 4. Ex vivo permeation profile of LRDP from transdermal 
patches through rat abdominal skin, mean ± S.D (n=3)15 Transdermal patches of lercanidipine hydrochloride
operating release mechanism. The n values obtained 
(0.527 to 0.626) by this equation indicated that the 
drug release was by non-fickian model. 
  
Ex-vivo permeation studies 
The results of ex-vivo drug permeation studies from 
transdermal patches are shown in table 2 and figure 
4. The formulation A1 exhibited the greatest (2644.5 
µg/cm2)  cumulative  amount  of  drug  permeation, 
which was significantly (p<0.05) different compared 
to the lowest value observed with the formulation 
A6 (1663.4) during 24 hrs. The flux obtained with 
formulation A1 was found to be maximum (106.5 
µg/cm2/hr).  When the permeability coefficients of 
different formulations were compared, A1 was found 
to have highest value (2.8 ×10-2 cm hr-1). When the 
cumulative amount of the drug permeated per square 
centimeter of patches through the rat abdominal skin 
was plotted against time, it was found that permeation 
profiles of drug follow Higuchi’s equation as it was 
evidenced  by  correlation  coefficients  (r2  =0.93  to 
0.99) better than first order (r2=0.54 to 0.68) and zero 
order kinetics (r2=0.91 to 0.98). As the proportion of 
HPMC increased in all formulations, permeation was 
increased. As described by Rao and Diwan, initial 
rapid dissolution of the hydrophilic polymer occurs 
when the patch is in contact with the hydrated skin, 
resulting in the accumulation of high amounts of drug 
in the skin surface and thus leading to saturation of 
the skin with drug molecules at all times (23).
Primary skin irritancy studies
The primary skin irritancy study of the transdermal 
patches, placebo patch and patch A1 showed a skin 
irritation score (erythema and edema) of less than 
2 (Table 3). According to Draize et al., (18) com-
pounds producing scores of 2 or less are considered 
non-irritant.  Hence,  the  transdermal  patches  were 
free of skin irritation.
CONCLUSIONS
Based on the results of this study, it may be concluded 
that  polymers  selected  were  better  suited  for  the 
development of TDDS of LRDP and the formulation 
A1 may be used for further pharmacokinetic and 
pharmacodynamic studies in humans or animals.
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